Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
Clavio M, Miglino M, Spriano M, Pietrasanta D, Vallebella E, Celesti L, Canepa L, Pierri I, Cavaliere M, Ballerini F, Beltrami G, Rossi E, Vimercati R, Bruni R, Congiu M, Nati S, Damasio E, Santini G, Gobbi M. Clavio M, et al. Among authors: pietrasanta d. Eur J Haematol. 1998 Sep;61(3):197-203. doi: 10.1111/j.1600-0609.1998.tb01084.x. Eur J Haematol. 1998. PMID: 9753416
Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients.
Clavio M, Casciaro S, Gatti AM, Spriano M, Bonanni F, Poggi A, Vallebella E, Pietrasanta D, Prencipe E, Goretti R, Vimercati R, Rossi E, Masoudi B, Ghio R, Boccaccio P, Ricciardi S, Damasio E, Gobbi M. Clavio M, et al. Among authors: pietrasanta d. Haematologica. 1996 May-Jun;81(3):238-44. Haematologica. 1996. PMID: 8767529 Clinical Trial.
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
Miglino M, Berisso G, Grasso R, Canepa L, Clavio M, Pierri I, Pietrasanta D, Gatto S, Varaldo R, Ballerini F, Verdiani S, Casarino L, DeStefano F, Sessarego M, Dominietto A, Raiola AM, Bregante S, di Grazia C, Gobbi M, Bacigalupo A. Miglino M, et al. Among authors: pietrasanta d. Bone Marrow Transplant. 2002 Nov;30(9):579-85. doi: 10.1038/sj.bmt.1703659. Bone Marrow Transplant. 2002. PMID: 12407432
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Mendicino F, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Cutrona G, Jaksic O, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: d arrigo g, pietrasanta d. Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28. Eur J Haematol. 2021. PMID: 33378569 Free article.
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).
Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F, Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G, Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice I, Della Starza I, De Propris MS, Raponi S, Guarini AR, Foà R. Mauro FR, et al. Among authors: pietrasanta d. Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705. Haematologica. 2020. PMID: 33131259 Free PMC article. No abstract available.
48 results